Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials

• Main Authors: April W. Armstrong (Author), Matthias Augustin (Author), Jennifer L. Beaumont (Author), Tan P. Pham (Author), Stacie Hudgens (Author), Kenneth B. Gordon (Author), Joe Zhuo (Author), Brandon Becker (Author), Yichen Zhong (Author), Renata M. Kisa (Author), Subhashis Banerjee (Author), Kim A. Papp (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2024-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Introduction Deucravacitinib, a novel, oral, selective allosteric tyrosine kinase 2 inhibitor, demonstrated superiority versus placebo and apremilast in the POETYK PSO-1 and PSO-2 studies. We describe patient-reported outcomes with deucravacitinib treatment versus placebo and apremilast in...